NPS Pharma (NPSP) Cash Flow Statement

Click line-items for a historical chart and %

Net loss
Depreciation and amortization	3.34M
Accretion of premium (discount) on marketable investment securities	3.21M
Non-cash interest expense	7.28M
Non-cash reduction in interest accrual/change in royalty receivable	-40.3M
Realized gain on marketable investment securities
Compensation expense on share based awards	15M
Accounts receivable	-7.71M
Prepaid expenses, other current assets and other assets	138K
Accounts payable and accrued expenses	6.84M
Other liabilities	5.12M
Net cash used in operating activities
Sales of marketable investment securities	11.21M
Maturities of marketable investment securities	123.46M
Purchases of marketable investment securities	-107.28M
Acquisitions of equipment	-3.09M
Net cash used in investing activities
Principal payments on debt and capital lease obligation
Proceeds from issuance of non-recourse debt
Payment of debt issuance costs
Net proceeds from the sale of common stock and exercise of stock options
Decrease in restricted cash and cash equivalents
Net cash provided by financing activities
Effect of exchange rate changes on cash	-1.66M
Net increase in cash and cash equivalents	14.36M
Cash and cash equivalents at beginning of period	51.2M
Cash and cash equivalents at end of period	65.57M
Cash paid for interest	256K
Cash paid for income taxes	270K
Unrealized losses on marketable investment securities	-59K
Accrued acquisition of equipment	293K
Accrued offering costs
Debt issued in lieu of interest
Conversion of 5.75% convertible notes	16.54M

Entities mentioned with NPSP

View All Entities